- Why in news
- On 23 July 2026, the Science & Technology Minister told the Rajya Sabha how the BioE3 Policy is being implemented, citing projects, Bio-AI Hubs, biofoundries and State BioE3 Cells.
- What it is
- BioE3 (Biotechnology for Economy, Environment and Employment) is a policy approved by the Union Cabinet in August 2024. It aims to build a resilient biomanufacturing ecosystem for bio-based products. It is run mainly by the Department of Biotechnology (DBT) and its public sector company BIRAC.
- Policy name and approval
- BioE3 stands for Biotechnology for Economy, Environment and Employment. The Union Cabinet approved it in August 2024.
- Six thematic sectors
- These are bio-based chemicals/enzymes, smart proteins and functional foods, precision biotherapeutics, climate-resilient agriculture, carbon capture and utilization, and futuristic marine and space research.
- BioE3 Strain Resource Centre
- It is set up at BRIC-NCCS, Pune. It gives access to indigenous microbial strains with freedom-to-operate, cutting reliance on imported strains.
- Funding by DBT and BIRAC
- DBT gives academia grant-in-aid. BIRAC supports start-ups and academia by grant-in-aid, and SMEs and industry through cofunding and royalty sharing.
- State BioE3 Cells
- BioE3 Cells have been notified in Assam, Sikkim and Himachal Pradesh as State coordination units.
- Six thematic areas
- The Policy covers biobased chemicals, enzymes and APIs; smart proteins and functional foods; precision biotherapeutics; climate resilient agriculture; carbon capture and utilization; and marine and space research.
- Shared facilities (BioEnablers)
- The Policy plans Bio-AI Hubs, Biofoundries and Biomanufacturing Hubs across the country in PPP mode, under the 'Moolankur' BioEnablers name.
- Biomanufacturing Hubs
- They give startups, academia and SMEs shared pilot-scale and pre-commercial-scale facilities, bridging lab research and full-scale manufacturing.
- ISS microalgae experiment
- Three indigenous microalgae (Chlorella sorokiniana-I, Parachlorella kessleri-I, Dysmorphococcus globosus-HI) were tested on the ISS for effects of microgravity, CO2 and O2 levels.
- Cyanobacteria experiment
- An Indian Spirulina isolate and a fast-growing Synechococcus strain were tested on nitrate and urea in microgravity, towards biological life support for space missions.
- DBT-ICGEB Biofoundry
- The New Delhi facility uses bacteria and yeast as microbial platforms and can scale production up to 20 litres.
- 2030 target
- India aims for a USD 300 billion bioeconomy by 2030.
- Startups
- More than 11,800 biotech startups support the sector, which has more than doubled in size since 2020.
- RDI Fund
- The Research, Development and Innovation Fund has an outlay of Rs 1 lakh crore; BIRAC has a key role in backing biotech ventures under it.
- BIRAC
- BIRAC is the Biotechnology Industry Research Assistance Council, which helps connect research with industry and bring ideas to market.
Don’t confuse with DBT vs BIRAC: DBT is the government department for biotechnology. BIRAC is its public sector enterprise that funds start-ups, SMEs and industry.
Don’t confuse with Biofoundry vs Biomanufacturing Hub: A biofoundry gives early scale-up of proof-of-concept work using automation and the Design-Build-Test-Learn cycle. A hub offers larger shared pilot and pre-commercial-scale capacity.
Don’t confuse with Microalgae vs cyanobacteria: Chlorella and related species are eukaryotic microalgae. Spirulina and Synechococcus are cyanobacteria, which are prokaryotes.
Don’t confuse with BioE3 vs. BIRAC: BioE3 is a policy for the bioeconomy. BIRAC is an agency that funds and supports biotech startups and innovation.
Don’t confuse with IBER vs. BIRAC Impact Report: IBER measures the size of India's bioeconomy. The BIRAC Impact Report shows the outcomes of BIRAC's funding and incubation.
Schemes: 52 Prelims questions since 2013, 10 in Prelims 2026 alone. They test features, the period and who funds it. In Mains, 33 news-triggered questions, mostly GS3.
Why it matters
- Builds a domestic biomanufacturing base and cuts import dependence on strains, chemicals and APIs.
- Links the bioeconomy with climate goals through carbon capture and bio-based alternatives.
- Shared facilities cut upfront costs for startups and SMEs, helping move lab innovations to market.
- Space experiments with algae and cyanobacteria point to CO2 capture and food supply in life support systems.
- Biotech now drives growth in healthcare, agriculture, climate solutions and sustainable manufacturing.
- Bio-based industries can cut dependence on fossil-based products and create jobs.
Problems
- Only three States have so far notified BioE3 Cells, so Centre-State coordination is uneven.
- Scaling from pilot to commercial production needs shared infrastructure, finance and regulatory clarity.
- Scale-up from lab to commercial production is hard and capital-intensive; the Delhi biofoundry reaches only 20 litres.
- PPP-based shared infrastructure needs steady funding and skilled manpower.
- Scale-up and commercialisation of lab innovations needs long-term capital and shared infrastructure.
- Talent and startup activity are concentrated in a few cities, so tier-2 and tier-3 cities need support.
Way forward
- Speed up State BioE3 Action Plans and Cells.
- Expand biofoundries and biomanufacturing hubs, and link them with industry for commercial scale-up.
- Build more pilot and commercial-scale hubs with regulatory support and training in bio-automation.
- Link research outputs to industry partners for market entry.
- Build shared facilities such as bio foundries and biomanufacturing platforms, and channel RDI Fund money to scale-up projects.
- Strengthen industry-academia links and support young researchers and women entrepreneurs.
Put in your answer
Strain Resource Centre: The SRC provides indigenous strains with freedom-to-operate, supporting Make in India.
BioE3 Policy: Approved by the Union Cabinet in August 2024; six thematic areas and BioEnablers to build biomanufacturing capacity.
Biofoundry example: The DBT-ICGEB Biofoundry replaces slow manual processes with bio-automation and AI in the DBTL cycle.
Bioeconomy data: India's bioeconomy was USD 195.3 billion in 2025, about 4.8% of GDP, with a CAGR of nearly 18%.
BioE3 focus areas: The policy promotes precision biotherapeutics, smart proteins, climate-resilient agriculture, bio-based chemicals and carbon capture.
- 2025Mains GS3 · Q6How can biotechnology help India achieve clean-tech energy independence by 2047
- 2018Mains GS3 · Q15Why biotechnology activity is high in India and how it benefited biopharma
- 2021Mains GS3 · Q15Applied biotechnology achievements and how they uplift poorer sections
UPSC’s own questions that come close to this issue, from our Prelims and Mains banks.
Prelims practice · Statements
Ours, not from a UPSC paper
Consider the following statements:
- 1.The BioE3 Policy was approved by the Union Cabinet in August 2024.
- 2.Under the BioE3 Policy, BIRAC supports SMEs and industries only through grant-in-aid.
- 3.The BioE3 Strain Resource Centre has been established at BRIC-NCCS, Pune.
Which of the statements given above is/are correct?
True or false?
1 of 3
Statements the way Prelims prints them. Say first, then see the fact.
1.The BioE3 Policy was approved by the Union Cabinet in August 2024.
True. Cabinet approval came in August 2024.
2.The BioE3 Strain Resource Centre has been established at BRIC-NCCS, Pune.
True. It is at BRIC-NCCS, Pune.
3.BioE3 Cells as State coordination units have so far been notified in Assam, Sikkim and Himachal Pradesh.
True. These three States have notified BioE3 Cells.
Written by us from the release, not by UPSC; checked by a second model.
Worth revising until Prelims 2028: most news questions come within two years of the event.